Financial Market Analysis & Investment Research Partly open
Eli Lilly (LLY): Weight-Loss Stock
Eli Lilly is the first pharmaceutical company with a market capitalization of about one trillion dollars: revenue for the second quarter of 2026 rose by 48%, and Mounjaro became the world’s best-selling drug. But the same earnings report tells another story—realized prices fell by 13%, an agreement with the U.S. government is reshaping the economics of the entire class of anti-obesity drugs, and the company’s own drug, Foundayo, is still significantly lagging behind its competitor. Let’s break down what all this means for the stock.
Already subscribed to «Financial Market Analysis & Investment Research»? Then sign in to read it. Sign in
Full version
The closed part follows
The full material is available with the «Financial Market Analysis & Investment Research 42$» subscription, or as a single view for $10.
- the full set of indicators and market factors;
- an interpretation of the current picture;
- conclusions and the signals that follow.
Sign in or register — then you can buy this material separately.
